Flamel Technologies SA (FLML)
-NasdaqGM 4.66 
0.04(0.87%) May 24, 4:00PM EDT
| Prev Close: | 4.62 |
|---|
| Open: | 4.58 |
|---|
| Bid: | N/A |
|---|
| Ask: | 5.25 x 100 |
|---|
| 1y Target Est: | 10.00 |
|---|
| Beta: | 1.3 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 4.42 - 4.68 |
|---|
| 52wk Range: | 2.85 - 5.62 |
|---|
| Volume: | 38,138 |
|---|
| Avg Vol (3m): | 46,248 |
|---|
| Market Cap: | 118.43M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.48 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Flamel Technologies Obtains Rights to Two Molecules of Trigger Lock Product LineMarketwired(Thu, May 23)
- Flamel Technologies S.A. Shares Cross Below 200 DMAat TheStreet(Thu, May 9)
- Flamel Technologies' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Flamel Technologies Announces First Quarter 2013 ResultsMarketwired(Tue, May 7)
- Q1 2013 Flamel Technologies Earnings Release - Before Market OpenCCBN(Tue, May 7)
- FLAMEL TECHNOLOGIES SA FinancialsEDGAR Online Financials(Sat, May 4)
- Learn Which Antibody Companies Show Show a Higher Probability of Success; Antibodies Have a Higher Track Record of M&A and More Predictable Toxicology ProfileWall Street Transcript(Fri, May 3)
- Flamel Technologies Announces Projected Release Date of First Quarter 2013 Results and Conference CallMarketwired(Tue, Apr 23)
- Flamel shares rise after lawsuit tossed outAP(Fri, Mar 22)
- Judge Dismisses 2007 Class Action Case Against Flamel TechnologiesMarketwired(Fri, Mar 22)
- Flamel: Near-Term, Under The Radar FDA Catalyst Tradeat Seeking Alpha(Thu, Mar 21)
- European Exposure Slows Down Large Medical Device Companies; Holding Smaller Names May Result in More Upside When Investing in This Healthcare Segment, According to Expert Equity AnalystWall Street Transcript(Mon, Mar 18)
- 5 Stocks Under $10 Triggering Breakoutsat TheStreet(Thu, Mar 14)
- Flamel's CEO Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Feb 28)
- Flamel Technologies Announces Fourth Quarter and Full Year 2012 ResultsMarketwired(Thu, Feb 28)
Key Statistics
| Forward P/E (1 yr): | 116.50 |
|---|
| P/S (ttm): | 4.92 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.99 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.27 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | 0.02 |
|---|
Business Summary
Flamel Technologies S.A., a biopharmaceutical company, engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer based technology in the United Kingdom, Ireland, the United States,...
View More